Skip to main content
. Author manuscript; available in PMC: 2014 Jul 15.
Published in final edited form as: Cancer. 2013 Apr 12;119(14):2582–2592. doi: 10.1002/cncr.28017

Figure 6.

Figure 6

[a] Median OS of patients with stage III/IV pure USC, mixed USC, and OSC histologies was 221, 675, and 1306 days, respectively (p<0.0001). [b] Among patients with USC, tubulin-β-III overexpression stratifies poor clinical outcome. Median OS in patients with low and high expression was 615 versus 165 days, respectively (p=0.044). [c] In this same cohort, p-glycoprotein overexpression had no prognostic utility (p=0.69). Box-plots demonstrate median, interquartile range, and overall range of copy number values for [d] tubulin-β-III and [e] p-glycoprotein.